Baseline and post-therapy characteristics of all subjects (column 1 “All Subjects n = 462”) followed by the same dataset stratified by tropism switch categories determined by population-sequencing (columns 2–5).

aAge was categorized as follows: under 30, 30–39, 40–49, and 50 or more.
bDuration (in months) between HAART-initiation and virologic suppression defined as 500 copies/mL.
cAdherence ≥95% was defined as ≥95% compliance of prescription refills over first 12 months of therapy initiation.d PI-containing therapy: drug category of a patient's first HAART therapy.
eNNRTI-containing therapy: drug category of a patient's first HAART therapy
fp-values were calculated based on comparisons between groups “Remained R5” and “R5-to-non-R5”.
gFisher's Exact test comparing PI and NNRTI-containing therapy against Remained R5 and R5-to-non-R5 switch.